Fennec Pharmaceuticals Statistics

Total Valuation

Fennec Pharmaceuticals has a market cap or net worth of CAD 204.14 million. The enterprise value is 192.64 million.

Market Cap	204.14M
Enterprise Value	192.64M

Important Dates

The last earnings date was Tuesday, November 12, 2024.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+2.34%
Shares Change (QoQ)	+0.27%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	13.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-125.86
EV / Sales	2.79
EV / EBITDA	n/a
EV / EBIT	81.78
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.80

Current Ratio	7.80
Quick Ratio	7.16
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	0.41

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	2.70%
Return on Capital (ROIC)	5.00%
Revenue Per Employee	2.30M
Profits Per Employee	-52,780
Employee Count	29
Asset Turnover	1.27
Inventory Turnover	2.22

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.76% in the last 52 weeks. The beta is 0.25, so Fennec Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.25
52-Week Price Change	-34.76%
50-Day Moving Average	6.40
200-Day Moving Average	9.85
Relative Strength Index (RSI)	68.81
Average Volume (20 Days)	2,246

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	18.54

Income Statement

In the last 12 months, Fennec Pharmaceuticals had revenue of CAD 66.67 million and -1.53 million in losses. Loss per share was -0.06.

Revenue	66.67M
Gross Profit	62.34M
Operating Income	2.28M
Pretax Income	-1.53M
Net Income	-1.53M
EBITDA	n/a
EBIT	2.28M
Loss Per Share	-0.06

Full Income Statement

Balance Sheet

The company has 54.47 million in cash and 43.37 million in debt, giving a net cash position of 11.10 million.

Cash & Cash Equivalents	54.47M
Total Debt	43.37M
Net Cash	11.10M
Net Cash Per Share	n/a
Equity (Book Value)	-6.99M
Book Value Per Share	-0.25
Working Capital	68.26M

Full Balance Sheet

Cash Flow

Operating Cash Flow	31.87M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 93.52%, with operating and profit margins of 3.41% and -2.30%.

Gross Margin	93.52%
Operating Margin	3.41%
Pretax Margin	-2.30%
Profit Margin	-2.30%
EBITDA Margin	n/a
EBIT Margin	3.41%
FCF Margin	n/a

Dividends & Yields

Fennec Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.34%
Shareholder Yield	-2.34%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on September 5, 2014. It was a reverse split with a ratio of 0.3333333.

Last Split Date	Sep 5, 2014
Split Type	Reverse
Split Ratio	0.3333333

Scores

Fennec Pharmaceuticals has an Altman Z-Score of -1.17. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.17
Piotroski F-Score	n/a